The Histone Deacetylase Inhibitors LAQ824 and LBH589 Do Not Require Death Receptor Signaling or a Functional Apoptosome to Mediate Tumor Cell Death or Therapeutic Efficacy

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2009 Apr 23

PMID 19383971

Citations 65

Authors

Leigh Ellis

Michael Bots

Ralph K Lindemann

Jessica E Bolden

Andrea Newbold

Leonie A Cluse

Clare L Scott

Andreas Strasser

Peter Atadja

Scott W Lowe

Ricky W Johnstone

Affiliations

Soon will be listed here.

Abstract

LAQ824 and LBH589 (panobinostat) are histone deacetylase inhibitors (HDACi) developed as cancer therapeutics and we have used the Emu-myc lymphoma model to identify the molecular events required for their antitumor effects. Induction of tumor cell death was necessary for these agents to mediate therapeutic responses in vivo and both HDACi engaged the intrinsic apoptotic cascade that did not require p53. Death receptor pathway blockade had no effect on the therapeutic activities of LAQ824 and LBH589; however, overexpression of Bcl-2 or Bcl-X(L) protected lymphoma cells from HDACi-induced killing and suppressed their therapeutic activities. Deletion of Apaf-1 or Caspase-9 delayed HDACi-induced lymphoma killing in vitro and in vivo, associated with suppression of many biochemical indicators of apoptosis, but did not provide long-term resistance to these agents and failed to inhibit their therapeutic activities. Emu-myc lymphomas lacking a functional apoptosome displayed morphologic and biochemical features of autophagy after treatment with LAQ824 and LBH589, indicating that, in the absence of a complete intrinsic apoptosis pathway involving apoptosome formation, these HDACi can still mediate a therapeutic response. Our data indicate that damage to the mitochondria is the key event necessary for LAQ824 and LBH589 to mediate tumor cell death and a robust therapeutic response.

Citing Articles

Insights into Metabolic Reprogramming in Tumor Evolution and Therapy.

Chiu C, Guerrero J, Regalado R, Zhou J, Zamora M, Notarte K Cancers (Basel). 2024; 16(20).

PMID: 39456607 PMC: 11506062. DOI: 10.3390/cancers16203513.

Inhibition of Notch Signaling Enhances Antitumor Activity of Histone Deacetylase Inhibitor LAQ824.

Mei Q, Xu X, Gao D, Xu Y, Yang J Int J Mol Sci. 2023; 24(17).

PMID: 37686467 PMC: 10487749. DOI: 10.3390/ijms241713660.

Advances in epigenetic modifications of autophagic process in pulmonary hypertension.

Mao M, Song S, Li X, Lu J, Li J, Zhao W Front Immunol. 2023; 14:1206406.

PMID: 37398657 PMC: 10313199. DOI: 10.3389/fimmu.2023.1206406.

Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies.

Markouli M, Strepkos D, Piperi C Int J Mol Sci. 2022; 23(21).

PMID: 36362442 PMC: 9654260. DOI: 10.3390/ijms232113657.

Single-cell profiling-guided combination therapy of c-Fos and histone deacetylase inhibitors in diffuse large B-cell lymphoma.

Wang L, Wu Z, Xia Y, Lu X, Li J, Fan L Clin Transl Med. 2022; 12(5):e798.

PMID: 35522945 PMC: 9076017. DOI: 10.1002/ctm2.798.

References

Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F . Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005; 280(29):26729-34. DOI: 10.1074/jbc.C500186200. View

Allen J, Zhang X, Scott C, Boyle G, Hersey P, Strasser A . Is Apaf-1 expression frequently abrogated in melanoma?. Cell Death Differ. 2005; 12(6):680-1. DOI: 10.1038/sj.cdd.4401634. View

Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, Remiszewski S . Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp. 2004; 259:249-66. View

Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F . A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006; 12(15):4628-35. DOI: 10.1158/1078-0432.CCR-06-0511. View

Scarlatti F, Bauvy C, Ventruti A, Sala G, Cluzeaud F, Vandewalle A . Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J Biol Chem. 2004; 279(18):18384-91. DOI: 10.1074/jbc.M313561200. View

Marsden V, Kaufmann T, OReilly L, Adams J, Strasser A . Apaf-1 and caspase-9 are required for cytokine withdrawal-induced apoptosis of mast cells but dispensable for their functional and clonogenic death. Blood. 2005; 107(5):1872-7. DOI: 10.1182/blood-2005-05-2160. View

Catley L, Weisberg E, Tai Y, Atadja P, Remiszewski S, Hideshima T . NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003; 102(7):2615-22. DOI: 10.1182/blood-2003-01-0233. View

Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J . Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003; 63(16):5126-35. View

Ekert P, Read S, Silke J, Marsden V, Kaufmann H, Hawkins C . Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die. J Cell Biol. 2004; 165(6):835-42. PMC: 2172390. DOI: 10.1083/jcb.200312031. View

10.

Lund A, van Lohuizen M . Epigenetics and cancer. Genes Dev. 2004; 18(19):2315-35. DOI: 10.1101/gad.1232504. View

11.

Kroemer G, Jaattela M . Lysosomes and autophagy in cell death control. Nat Rev Cancer. 2005; 5(11):886-97. DOI: 10.1038/nrc1738. View

12.

Mathew R, Karantza-Wadsworth V, White E . Role of autophagy in cancer. Nat Rev Cancer. 2007; 7(12):961-7. PMC: 2866167. DOI: 10.1038/nrc2254. View

13.

Johnstone R, Ruefli A, Lowe S . Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002; 108(2):153-64. DOI: 10.1016/s0092-8674(02)00625-6. View

14.

Baylin S, Ohm J . Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer. 2006; 6(2):107-16. DOI: 10.1038/nrc1799. View

15.

Wang S, Yan-Neale Y, Cai R, Alimov I, Cohen D . Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824. Cell Cycle. 2006; 5(15):1662-8. DOI: 10.4161/cc.5.15.3099. View

16.

Bolden J, Peart M, Johnstone R . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5(9):769-84. DOI: 10.1038/nrd2133. View

17.

Janssen K, Pohlmann S, Janicke R, Schulze-Osthoff K, Fischer U . Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment. Blood. 2007; 110(10):3662-72. DOI: 10.1182/blood-2007-02-073213. View

18.

Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A . Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med. 2004; 11(1):71-6. DOI: 10.1038/nm1160. View

19.

Schafer Z, Kornbluth S . The apoptosome: physiological, developmental, and pathological modes of regulation. Dev Cell. 2006; 10(5):549-61. DOI: 10.1016/j.devcel.2006.04.008. View

20.

Adams J, Harris A, Pinkert C, Corcoran L, Alexander W, Cory S . The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985; 318(6046):533-8. DOI: 10.1038/318533a0. View